Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 11, 2017, Pages

  Morley, Lara C ^a   Tang, Thomas ^b   Yasmin, Ephia ^a   Norman, Robert J ^c   Balen, Adam H ^d  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ROYAL MATERNITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d SEACROFT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLOMIFENE CITRATE; DEXTRO CHIRO INOSITOL; GLUCOSE; INOSITOL DERIVATIVE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CLOMIFENE; INOSITOL;

AMENORRHEA AND OLIGOMENORRHEA; ANOVULATION; BIRTH RATE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HORMONE BLOOD LEVEL; HUMAN; LIVE BIRTH; MENSTRUATION; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SPONTANEOUS ABORTION; SUBFERTILITY; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL LEVEL; WAIST HIP RATIO; COMPLICATION; FEMALE; FEMALE INFERTILITY; INSULIN RESISTANCE; META ANALYSIS; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

ABORTION, SPONTANEOUS; ANOVULATION; CLOMIPHENE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INOSITOL; INSULIN RESISTANCE; LIVE BIRTH; METFORMIN; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 85031803755     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003053.pub6     Document Type: Review

References (171)

1. Ayaz A, Alwan Y, Farooq MU. Efficacy of combined metformin-clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life 2013;6:199-201. 7057076
2. Ayaz A, Alwan Y, Farooq MU. Metformin-clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences 2013;6:15-8. 2838468
3. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility 2004;82:893-902. 2838470
4. Begum H, Chowdhury TA, Begum F, Begum SN, Kabir N, Haque MDA. Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology 2014;29:15-20. 7057078
5. Ben Ayed B, Dammak Dit Mlik S, Ben Arab H, Trabelssi H, Chahtour H, Mathlouthi N. Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome. Tunisie Medicale 2009;87(1):43-8. 2838472
6. Boudhrâa K, Jellouli MA, Amri M, Farhat M, Torkhani F, Gara MF. Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale 2010;88(5):335-40. 2838474
7. Aigner E, Bachofner N, Klein K, De Geyter C, Hohla F, Patsch W, et al. Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism 2009;94(4):1229-35. 2838476
8. Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Epidemiology 2004;89:3835-40. 2838477
9. Carmina E, Lobo RA. Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology 2004;191:1580-4. 2838479
10. Chou KH, von Eye Corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Hormone and Metabolic Research 2003;35:86-91. 2838481
11. Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A, von Wolff M, Hamann A, et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2006;91:946-52. 2838483
12. El-Biely MM, Habba M. The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertility Society Journal 2001;6(1):43-9. 2838485
13. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2002;87(2):569-74. 2838487
14. Fleming R, Hopkinson ZE, Wallace E, Greer IA, Sattar N. Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility 2000; Vol. 3, issue 4:389-90. 2838488
15. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. European Review for Medical and Pharmacological Sciences 2003;7:151-9. [Original article]2838490
16. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences 2007;11(5):347-54. 2838491
17. Glintborg D, Frystyk J, Hojlund K, Andersen KK, Henriksen JE, Hermann A, et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clinical Endocrinology (Oxford) 2008;68(2):165-74. 2838493
18. Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertility and Sterility 2006;86:385-97. 2838494
19. Glintborg D, Hojlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008;31:328-34. 2838495
20. Glintborg D, Stoving RK, Hagen C, Hermann AP, Frystyk J, Veldhuis JD, et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005;90:5605-12. [original article]2838496
21. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility 2004;82:421-9. 2838498
22. Hwu YM, Lin SY, Huang WY, Lin MH, Lee RK. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics 2005;90:39-43. 2838500
23. Jakubowicz DJ, Seppala M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2001;86(3):1126-33. 2838502
24. Kar S. Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts 2013;100(S359):P-730. 7057081
25. Kar S, Sanchita S. Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science 2015;8:197-201. 7057080
26. Karimzadeh M, Tayebi N, Eftekhar M, Sakhavat L, Taheripanah R, Zare F. The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal 2007;12(3):174-8. 2838504
27. Karimzadeh MA, Javedani M. An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertility and Sterility 2010;94(1):216-20. 2838506
28. Khorram O, Helliwell JP, Katz S, Bonpane CM, Jaramillo L Khorram O, et al. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility 2006;85:1448-51. 2838508
29. Lam PM, Tam WH, Ma RC, Cheung LP, Tsui MH, Tong PC, et al. The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome - a double-blind randomized placebo-controlled study. Fertility and Sterility 2011;96(2):445-51. 2838510
30. Cataldo N, Barnhart H, Legro R, Myers E, Schlaff W, Carr B, et al. Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2008;93(8):3147-7. 2838512
31. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2007;356:551-66. [original article]2838513
32. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial. British Journal of Obstetrics and Gynaecology 2006;113:817-24. 2838515
33. Machado RC, Machado NA, Geber S. Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction 2012;16(1):27-31. 2838517
34. Maciel GA, Soares Jr JM, Alves da Motta EL, Abi Haidar M, de Lima GR, Baracat EC, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility 2004;81:355-60. 2838519
35. Malkawi HY, Qublan HS. The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. Saudi Medical Journal 2002;23(6):663-6. [MEDLINE: 22065897]2838521
36. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Journal of Clinical Endocrinology and Metabolism 2000;85(1):139-46. 2838523
37. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, Van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006;332:1485. [original article]2838525
38. Moll E, Korevaar JC, Bossuyt PM, van der Veen F. Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction 2008;23(8):1830-4. 2838526
39. Moll E, Van Wely M, Lambalk CB, Bossuyt PM, Van der Veen F. Health-related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction 2012;27:3273-8. 7057082
40. Morin-Papunen L, Rantala AS, Unkila-Kallio L, Tiitinen A, Hippeläinen M, Perheentupa A, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. Journal of Clinical Endocrinology and Metabolism 2012;97:1492-1500. 2838528
41. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine 1998;338(26):1876-80. 2838530
42. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. New England Journal of Medicine 1999;340(17):1314-20. 2838532
43. Ng EHY, Wat NMS, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Human Reproduction 2001;16(8):1625-31. 2838534
44. Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabuccu R. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2005;123:204-11. 2838536
45. Otta CF, Wior M, Iraci GS, Kaplan R, Torres D, Gaido MI, et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. Gynecological Endocrinology 2010;26(3):173-8. 2838538
46. Palomba S, Orio F Jr, Falbo A, Manguso F, Russo T, Cascella T, et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005;90(7):4068-74. [original article]2838540
47. Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F. Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility 2006;86:1694-701. 2838541
48. Casimirri F, Biscotti M, Gambineri A, Calzoni F, Eliana B, Pasquali R. Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity 1997;21 Suppl 2:61. 2838543
49. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2000;85(8):2767-74. 2838544
50. Johnson NP, Bontekoe S, Stewart AW. Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial. Australian & New Zealand Journal of Obstetrics & Gynaecology 2011;51:252-6. 7057083
51. Johnson NP, Stewart AW, Falkiner J, Farquhar CM, Milsom S, Singh V-P, et al. on behalf of REACT-NZ (REproduction And Collaborative Trials in New Zealand), a multi-centre fertility trials group. PCOSMIC: a multi-centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction 2010;25(7):1675-83. [MEDLINE: 10.1093/humrep/deq100]2838546
52. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Human Reproduction 2006;21:1400-7. 2838548
53. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study. Fertility and Sterility 2007;87(1):202-6. 2838549
54. Romualdi D, Giuliani M, Cristello F, Fulghesu AM, Selvaggi L, Lanzone A, et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertility and Sterility 2010;93(7):2303-10. 2838551
55. Sahin Y, Yirmibes U, Kelestimur F, Aygen E. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2004;113:214-20. 2838553
56. Siebert T, Kruger T, Lombard C. Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics 2009;26(4):165-71. 2838555
57. Sturrock NDC, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology 2002;53(5):469-73. [MEDLINE: 2002180629]2838557
58. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human Reproduction 2006;21:80-9. 2838559
59. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Human Reproduction 2007;22(11):2967-73. [original article]2838561
60. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Obstetrics and Gynecological Survey 2008;63(2):96-8. 2838562
61. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility 2001;75:310-5. 2838564
62. Williams SC, Pastore LM, Shelly WB, Bailey AP, Baras DC, Bateman BG. A randomized, placebo-controlled study of the influence of instant-release metformin on response to clomiphene citrate and time to conception in polycystic ovary syndrome. Fertility and Sterility 2009;92 Suppl(3):105. 2838566
63. Yarali H, Yildiz BO, Demirol A, Zeyneloglu HB, Yigit N, Bukulmez O, et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction 2002;17(2):289-94. 2838568
64. Yarali H, Yyldyz B, Demirol A, Zeyneloglu H, Yigit N, Bukulmez O. Co-administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low-dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility 2001;76 Suppl(3):36. 2838569
65. Zain MM, Jamaluddin R, Ibrahim A, Norman RJ. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility 2009;91(2):514-21. 2838571
66. Abuelghar WM, Elkady OS, Khamees AA. Clomiphene citrate alone, in combination with metformin or in combination with pioglitazone as first line therapy in induction of ovulation in infertile women with polycystic ovary syndrome, a randomised controlled trial. Middle East Fertility Society Journal 2013;18:135-41. 2838643
67. Aroda V, Ciaraldi T, Burke P, Mudaliar S, Clopton P, Phillips S, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. Journal of Clinical Endocrinology and Metabolism 2009;94(2):469-76. 2838573
68. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2001;86(4):1626-32. [original article]2838577
69. Guyatt G, Weaver B, Cronin L, Dooley JA, Azziz R. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. Journal of Clinical Epidemiology 2004;57:1279-87. 2838578
70. Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, Ghazzi MN. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. Journal of Clinical Endocrinology and Metabolism 2003;88:5137-44. 2838579
71. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertility and Sterility 2003;79:932-7. 2838581
72. Chaudhry I, Nisa SU, Nia SU. Comparison between pioglitazone and metformin in terms of efficacy in patients with polycystic ovarian syndrome. Pakistan Journal of Medical and Health Sciences 2016;10:574-7. 7057085
73. Chaudhury K, Chaudhury S, Chowdhury S. Does metformin augment the ovulation inducing effects of clomiphene in non-obese women with polycystic ovary syndrome?. Journal of the Indian Medical Association 2008;106(10):643-8. 2838583
74. Costantino D, Minozzi G, Minozzi F, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. European Review for Medical and Pharmacological Sciences 2009;13(2):105-10. 2838585
75. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. Journal of Clinical Endocrinology and Metabolism 1995;80(7):2057-62. 2838587
76. Curi DD, Fonseca AM, Marcondes JA, Almeida JA, Bagnoli VR, Soares JM Jr, et al. Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecological Endocrinology 2010;28:182-5. 2838589
77. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertility and Sterility 1999;72(2):282-5. 2838591
78. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1996;81(9):3299-306. 2838593
79. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction 2002;17(7):1729-37. [MEDLINE: 785]2838595
80. Farzadi L, Salman S. Metformin-therapy effects in 50 clomiphene citrate resistant PCOS patients. Journal of Medical Science 2006;6:765-71. 2838597
81. Heathcote G, Forbes K, Lee A, Gregor M, Luscombe G, Boothroyd C. Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double-blind, placebo-controlled trial. Draft paper supplied by authors. 2838599
82. Hou J, Yu J, Wei M. Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula "tiangui fang". Zhongguo Zhong Xi Yi Jie He Za Zhi 2000;20(8):589-92. 2838601
83. Ibanez L, Valls C, Ferrer A, Ong K, Dunger D, De-Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. Journal of Clinical Endocrinology and Metabolism 2002;87(6):2870-4. [MEDLINE: 22045399]2838603
84. Kazerooni T, Ghaffarpasand F, Kazerooni Y, Kazerooni M, Setoodeh S. Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics 2009;107(1):50-3. 2838607
85. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. European Journal of Endocrinology 2002;147(2):217-21. [MEDLINE: 782]2838609
86. Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertility and Sterility 2002;77(1):101-6. 2838611
87. Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertility and Sterility 2011;95(3):1059-66. 2838613
88. Leanza V, Coco L, Grasso F, Leanza G, Zarbo G, Palumbo M. Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome. Minerva Ginecologica 2014;66(3):299-301. 2838647
89. Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1997;82(6):1687-91. 2838615
90. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology and Metabolism 2000;85(9):3161-8. [DOI: 10.1210/jcem.85.9.6792]2838619
91. Morin-Papunen L, Rantala A, Unkila-Kallio L, Tiitinen A, Hippelainen M, Tinkanen H, et al. Metformin improves pregnancy and live birth rates in women with polycystic ovary syndrome - a multicentre placebo-controlled randomised trial. 26th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE Rome Italy 2010;25:i67-8. 2838621
92. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine 1996;335(9):617-23. 2838623
93. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. Journal of Clinical Endocrinology and Metabolism 1997;82(12):4075-9. 2838625
94. Palomba S, Falbo A, Di Cello A, Cappiello F, Tolino A, Zullo F. Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertility and Sterility 2011;96:1128-33. 2838627
95. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and Sterility 2009;91:1750-4. 2838629
96. Ramzy A, El-Kateb S, Al-Inany H, Aboulmaaty Z, Badie M. The use of metformin in overweight and lean infertile patients with polycystic ovarian syndrome: a randomised controlled trial. Middle East Fertility Society Journal 2003;8:143-9. 2838631
97. Refaie A, Ibrahim G, Oash S. Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Jounal 2005;10:142-9. 2838633
98. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertility and Sterility 2006;85:428-35. 2838635
99. Salman SA, Farghaly TA, Attallah DA, Abdel-Hafeez HA, Shaaban OM. Insulin sensitizing agent (metformin) improves clinical pregnancy rate in clomiphene citrate resistant polycystic ovarian syndrome patients with acanthosis nigricans. Fertility and Sterility 2014;102(Supplement 3):e139. 2838649
100. Santonocito V, Rapisarda V, Abruzzo SRM, Pollicino R, Coco L, Zarbo G. Comparison between clomiphene citrate and metformin for induction of ovulatory cycles in infertile nonobese women with polycystic ovary syndrome. Giornale Italiano di Ostetricia e Ginecologia 2009;31(11-12):455-60. 2838637
101. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. Journal of the Society for Gynecologic Investigation 2003;10:99-104. 2838639
102. Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. European Review for Medical and Pharmacological Sciences 2011;15:452-7. 2838641
103. Abu Hashim H. Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online 2016;32:44-53.
104. Alebić MS, Bulum T, Stojanović N, Duvnjak L. Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine 2014;47:625-30.
105. Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Archives of Internal Medicine 2006;166:2081-6.
106. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2005;90:1929-35.
107. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. Journal of Clinical Endocrinology and Metabolism 2005;90:4650-8.
108. Balen AH. Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978-1-84184-5]
109. Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Human Reproduction Update 2016;22:687-708. [DOI: 10.1093/humupd/dmw025]
110. Bordewijk EM, Nahuis M, Costello MF, Van der Veen F, Tso LO, Mol BWJ, et al. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD009090.pub2]
111. Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Human Reproduction Update 2014;20:656-69.
112. Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstetrics and Gynecology 2004;103:219-24.
113. Celik C, Tasdemir N, Abali R, Bastu E, Yilmaz M. Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study. Fertility and Sterility 2014;101:1123-8.
114. Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One 2013;8:Epub ahead of print.
115. Costello MF, Eden JA. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertility and Sterility 2003;79:1-13.
116. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005552.pub2; PUBMED: 17253562]
117. De Frène V, Vansteelandt S, T'Sjoen G, Gerris J, Somers S, Vercruysse L, et al. A retrospective study of the pregnancy, delivery and neonatal outcome in overweight versus normal weight women with polycystic ovary syndrome. Human Reproduction 2014;29:2333-8.
118. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
119. Diamanti-Kandarakis E, Christakou CD, Kandarakis E, Economou F. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology 2010;162:193-212.
120. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2006;91:48-53.
121. European Medicines Agency. European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/10/news_detail_001368.jsp&mid=WC0b01ac058004d5c1&jsenabled=true Accessed 2011.
122. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004;19(1):41.
123. The Thessaloniki ESHRE/ASRM-sponsored PCOS consensus workshop group. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction 2008;23:462-77.
124. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility 2012;97:28-38. [PUBMED: 22153789]
125. FDA (Federal Drug Administration). www.fda.gov Accessed 14 January 2003.
126. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173:309-14.
127. Franik S, Kremer JAN, Nelen W, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD010287.pub2]
128. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007;334:299.
129. McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), Accessed 2015-2017.
130. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. The American Journal of Medicine 2003;114:299-306.
131. Hahn S, Tan S, Sack S, Kimmig R, Quadbeck B, Mann K, et al. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Experimental and Clinical Endocrinology & Diabetes 2007;115:130-5.
132. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
133. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
134. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 1999;84:1470-4.
135. Jensterle M, Kocjan T, Pfeifer M, Janez A. Short-term intervention with liraglutide improved eating behaviour in obese women with polycystic ovary syndrome. Endocrine Research 2014;40:133-8.
136. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology (Oxford) 1992;36:105-11.
137. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002;346:393-403.
138. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370(9593):1129-36.
139. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
140. Legro RS. Type 2 diabetes and polycystic ovary syndrome. Fertility and Sterility 2006;86 Suppl 1:16-7.
141. Legro RS, Myers ER, Barnhart HX, Carson SA, Diamond MP, Carr BR, et al. and Reproductive Medicine Network. The Pregnancy in Polycystic Ovary Syndrome Study: baseline characteristics of the randomized cohort including racial effects. Fertility and Sterility 2006;86(4):914-33.
142. Lord J, Wilkin T. Polycystic ovary syndrome and fat distribution: the central issue?. Hum Fertil (Camb) 2002;5:67-71.
143. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction 2010;25:544-51.
144. Misso ML, Costello MF, Garrubba M, Wong J, Hart R, Rombauts L, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2013;19:2-11.
145. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD007506.pub3]
146. Moran LJ, Deeks AA, Gibson-Helm ME, Teede HJ. Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction 2012;27:2082-8.
147. Palomba S, Pasquali R, Orio Jr F, Nestler JE. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clinical Endocrinology 2009;70:311-21.
148. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Human Reproduction Update 2003;9:359-72.
149. Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nature Reviews. Endocrinology 2014;10:143-56. [DOI: 10.1038/nrendo.2013.256]
150. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Human Reproduction 2006;21:1400-7.
151. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study. Fertility and Sterility 2007;87(1):202-6.
152. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
153. Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clinical Endocrinology (Oxford) 1993;39:351-5.
154. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
155. Schünemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook.
156. Siebert, TI, Viola MI, Steyn DW, Kruger TF. Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis. Gynecologic and Obstetric Investigation 2012;73:304-13.
157. Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhao TM. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertility and Sterility 2007;88(5):1389-95.
158. Stein. Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology 1935;29:181-91.
159. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Human Reproduction 2013;28:544-51.
160. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
161. Tso L, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3]
162. Uusitupa M, Louheranta A, Lindstrom J, Valle T, Sundvall J, Eriksson J, et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition 2000;83 Suppl 1:137-42.
163. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetrics and Gynecology 1997;90:392-5.
164. Weerakiet S, Bunnag P, Phakdeekitcharoen B, Wansumrith S, Chanprasertyothin S, Jultanmas R, et al. Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: using the International Diabetes Federation criteria. Gynecological Endocrinology 2007;23:153-60.
165. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?. Clinical Endocrinology (Oxford) 2002;57:343-50.
166. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?. Clinical Endocrinology (Oxford) 2004;60:560-7.
167. Yki-Jarvinen H. Thiazolidinediones. New England Journal of Medicine 2004;351:1106-18.
168. Zhang Y, Ye J. Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharmacologica Sinica 2012;2:341-9.
169. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD003053]
170. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD003053.pub4; PUBMED: 20091537]
171. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD003053.pub5]